 |
|
|
| |
An Analysis of Neurologic and Psychiatric Adverse Events of Subjects Receiving the Investigational HIV-1 Maturation Inhibitor (MI) GSK3532795/BMS-955176
|
| |
| |
Reported by Jules Levin
9th IAS Conference on HIV Science; July 23-26, 2017; Paris, France
J Gan,1T Pene Dumitrescu,2B Shepherd,3H Sevinsky,4J Coumbis,5K Barker,3S Min,6M Lataillade,7SR Joshi7
1GlaxoSmithKline, Upper Providence, PA, USA; 2GlaxoSmithKline, Upper Merion, PA, USA; 3GlaxoSmithKline, Stockley Park, UK; 4ViiV Healthcare, Upper Providence, PA, USA; 5Bristol-Myers Squibb, Hopewell, NJ, USA; 6ViiV Healthcare, Research Triangle Park, NC, USA; 7ViiV Healthcare, Wallingford, CT, USA
|
| |
|
|
|
|
|
